IP Library Granted Patent US 10,179,911
Granted Patent B2
US 10,179,911 · App. 15/112,759 · Granted Jan 15, 2019

Negative selection and stringency modulation in continuous evolution systems

Inventors: David R. Liu (Lexington, MA); Jacob Charles Carlson (Somerville, MA); Ahmed Hussein Badran (Somerville, MA); Kevin Michael Esvelt (Cambridge, MA)
Assignee: President and Fellows of Harvard College
C12N15/1058C12N7/00C12N15/01C12N15/1024C12N15/1037C40B10/00C40B50/06C12N15/64C12N15/70C12N2795/14121C12N2795/14152
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,179,911
App. No.
15/112,759
Filed
Jul 20, 2016
Granted
Jan 15, 2019
Kind
B2
Art Unit
1639
USPC
506/9
Abstract

Strategies, systems, methods, reagents, and kits for phage-assisted continuous evolution are provided herein. These include strategies, systems, methods, reagents, and kits allowing for stringency modulation to evolve weakly active or inactive biomolecule variants, negative selection of undesired properties, and/or positive selection of desired properties.

Claims (27)

1. A method for modulating the selection stringency during viral-assisted evolution of a gene product, the method comprising:

(a) introducing host cells into a lagoon, wherein the host cell comprises a low selection stringency plasmid and a high selection stringency plasmid, wherein the low selection stringency plasmid comprises a viral gene required to package a selection viral vector into an infectious viral particle, wherein at least one gene required to package the selection viral vector into an infectious viral particle is expressed in response to a concentration of a small molecule, and wherein the high selection stringency plasmid comprises a second copy of the viral gene required to package the selection viral vector into the infectious viral particle, wherein at least one viral gene required to package the selection viral vector into an infectious viral particle is expressed in response to a desired activity property of a gene product encoded by the gene to be evolved or an evolution product thereof;

(b) introducing a selection viral vector comprising a gene to be evolved into a flow of host cells through a lagoon, wherein the gene to be evolved produces an active gene product or a weakly active or inactive gene product, wherein the active gene product has an activity that drives the expression of the viral gene required to package the selection viral vector into infectious viral particles in the high selection stringency plasmid and wherein the weakly active or inactive gene product has a relatively lower activity than the activity of the active gene product; and

(c) mutating the gene to be evolved within the flow of host cells, wherein the host cells are introduced through the lagoon at a flow rate that is faster than the replication rate of the host cells and slower than the replication rate of the virus thereby permitting replication of the selection viral vector in the lagoon.

2. The method of claim 1 , further comprising isolating the selection viral vector comprising an evolved product from the flow of cells and determining one or more properties of the evolved product.

3. The method of claim 1 , wherein the low selection stringency plasmid contains a drift promoter that is activated by a concentration of a small molecule inducer and/or prior viral infection.

4. The method of claim 1 , wherein the high selection stringency plasmid contains a promoter that is activated by a desired property of a gene product encoded by the gene to be evolved or an evolution product thereof.

5. The method of claim 4 , wherein the low selection stringency plasmid comprises a mutagenesis cassette under the control of a small-molecule inducible promoter.

6. The method of claim 5 , wherein the low selection stringency plasmid allows a high level of evolutionary drift to occur when the drift promoter is activated in response to a concentration of a small molecule inducer and/or prior viral infection.

7. The method of claim 6 , wherein the high selection stringency plasmid allows a low level of evolutionary drift to occur when the promoter is activated in response to a desired activity property of a gene product encoded by the gene to be evolved or an evolution product thereof.

8. The method of claim 2 , wherein the property of the gene to be evolved originated from a weakly active or inactive starting gene.

9. The method of claim 1 , wherein the high selection stringency comprises a T7 promoter.

10. The method of claim 1 , wherein the low selection stringency comprises a drift promoter that is activated by a small-molecule inducer and/or prior viral infection.

11. The method of claim 1 , wherein the drift promoter is a P psp-tet promoter.

12. The method of claim 1 , further comprising the use of negative selection and/or positive selection.

13. A method of using negative selection during viral-assisted evolution of a gene product, the method comprising:

(a) introducing host cells into a lagoon, wherein the host cell comprises a negative selection gene and a dominant negative mutant gene of a phage gene that decreases or abolishes packaging of the selection viral vector into infectious viral particles, wherein the dominant negative gene is expressed in response to an undesired activity of the gene to be evolved or an evolution product thereof or in response to a concentration of a small molecule inducer;

(b) introducing a mixture of selection viral vectors into a flow of host cells through a lagoon, wherein one type of selection viral vector comprises a negative selection gene comprising an undesired gene or gene encoding an undesired property of the gene to be evolved and wherein another type of selection viral vector comprises a positive selection gene comprising a desired gene or gene encoding a desired property of the gene to be evolved; and

(c) mutating the gene to be evolved within the flow of host cells, wherein the host cells are introduced through the lagoon at a flow rate that is faster than the replication rate of the host cells and slower than the replication rate of the virus thereby permitting replication of the selection viral vector in the lagoon.

14. A method of modulating the selection stringency and using negative selection during viral-assisted evolution of a gene product, the method comprising claim 1 .

15. The method of claim 1 , wherein the gene of interest to be evolved encodes a DNA-binding gene product.

16. The method of claim 1 , wherein expression of the gene required to package the selection phagemid into infectious particles is driven by a promoter comprising a desired DNA binding site for the gene product.

17. The method of claim 13 , wherein expression of the dominant negative mutant of the phage gene that decreases or abolishes packaging of the selection phagemids into infectious phage particles is driven by a promoter comprising an undesired DNA binding site for the gene product.

18. The method of claim 1 , wherein the host cells are introduced into lagoons from a chemostat.

19. The method of claim 1 , wherein the host cells are prokaryotic cells amenable to phage infection, replication, and production.

20. The method of claim 1 , wherein a gene that is required to package the selection viral vector into infectious viral particles is a gene that encodes for the pIII protein.

21. The method of claim 1 , wherein the selection viral vector comprises all viral genes required for the generation of viral particles, except for a full-length gene that is required to package the selection viral vector into infectious viral particles.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2017
From: BADRAN, AHMED HUSSEIN; CARLSON, JACOB; ESVELT, KEVIN M.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 041089/0984 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2017
From: LIU, DAVID R.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 041090/0021 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2017
From: HOWARD HUGHES MEDICAL INSTITUTE
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 041090/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2017
From: ESVELT, KEVIN M.; CARLSON, JACOB; BADRAN, AHMED HUSSEIN
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 041072/0613 →
CONFIRMATORY LICENSE Recorded Aug 30, 2016
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039863/0796 →
Continuity (2)
Provisional Application 61929378 · Jan 20, 2014
Related Publication 20160348096A1 · Dec 1, 2016
Cited By (23)
US 12,281,303 US 12,281,338 US 12,344,869 US 12,351,837 US 12,359,218 US 12,366,009 US 12,390,514 US 12,398,390 US 12,406,749 US 12,435,330 US 12,435,331 US 12,473,543 US 12,473,573 US 12,509,680 US 12,516,308 US 12,522,807 US 12,559,737 US 12,570,972 US 12,584,118 US 12,624,353 US 12,624,354 US 12,655,182 US 12,668,815